Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

"FONT-SIZE: 11pt; FONT-FAMILY: Sabon; LETTER-SPACING: 0pt; mso-ansi-language: PT-BR; mso-fareast-language: EN-US; mso-no-proof: no" xml:lang="PT-BR">Thomas Hungerbuehler +41 61 324 8425

Richard Jarvis +41 61 324 4353

North America:

Ronen Tamir +1 212 830 2433

Arun Nadiga
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Post Your Comments:
(Date:12/1/2008)...O, Dec. 1 TargeGen has announced t...from a multi-center, US-based clinical,trial of T... been scheduled at,the 2008 American Society of H... presentation are as follows:, Title: ...vailable, JAK2-Selective I...
(Date:12/1/2008)...stinence is still the best policy , , ROCH...new study from Mayo Clinic finds the use of the dr...holic hepatitis, an acute inflammation of the live...results of the study are published in the December...urnal.org/ ). , , VIDEO ALERT: Additional ...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/27/2008)...y finds the majority of acute lymphoblastic leukem... at the time of diagnosis , , MEMPHIS, Tenn...t St. Jude Children,s Research Hospital have ident...lls of children with acute lymphoblastic leukemia ...hway to designing treatments for ALL relapse in ch...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Progress toward new storage media 8631 1Progress toward new storage media 8631 2Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 1Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 2MU researchers advance health communication for at risk populations 27821 1MU researchers advance health communication for at risk populations 27821 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 1Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 3Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 4
...etary DNA delivery technology enables sustained,In...es,atherosclerosis progression in mouse model of h..., 2007 - Research conducted,at Cleveland Clinic an...ology,s 58th Annual Scientific Session showed that...inflammatory protein,interferon-beta (IFN-beta) us...
...oadministered with statins for only five weeks at,...hieved with,statins alone, with similarly favorabl... and CARLSBAD, Calif., March 26, 2007,/PRNewswire-... new,results from its Phase 2 clinical trial of IS...day at the of Cardiology,Annual Scientific Session...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:12/2/2008)...N, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Ch..." or "the Company") (Nasdaq: CSKI ), a leading,...over-the-counter drugs in,the People,s Republic o...Stanley) Hao was appointed Chief Financial Officer...,s Board of Directors. He replaces Yu-kun Zhang, ...
(Date:12/2/2008)...BURGH, Dec. 2 Mylan Inc....ubsidiary, Mylan Pharmaceuticals Inc., have entere...aceuticals Corp., Novartis,Corp. and Novartis Int...neric,version of Novartis, Femara(R). , My...ted: "We are very,pleased to have reached this ag...
(Date:12/2/2008)...NVILLE, Calif., Dec. 2 In response...n A Toxicity, Frequent Respiratory Infections, and...ovember 11th by 16 well known supplement experts, ... oil products pose no threat or compromise to cons...solutions that are low in natural Vitamin A. Accor...
(Date:12/2/2008)... SPEAK to collect and dissemin... Bellevue, Wash. (PRWEB) December ...ced the launch of a new initiative to focus public...eness . The official kick-off of SPEAK will occur ...acists (ASHP) 2008 Midyear Clinical Meeting, to be...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2
...ave limited benefit in the first-line treatment of...// according to a report in the April issue of Arc...rnals. However, a second report in the same issue ...may be effective in patients with another ulcer-ca...
...n (FDA) is alerting consumers to possible serious ...aminated with a deadly bacterium, Clostridium botu...lly fatal illness. The olives are made by Charlie ... and are being recalled by the manufacturer. No il...
...for liver cancer, says a US study. Using DNA isol... researchers at Columbia University's Mailman Scho...rly detection of liver cancer, says the study publ...of Clinical Cancer Research. The scientists exami...
...ke is an effective way of identifying prostate can...teoporosis, according to a research.// Researcher... Barcelona, Spain, looked at a cross-section of 37...t were receiving androgen-deprivation therapy (ADT...
Other Medicine News:Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available.
...heter is specifically designed for use with our CA...able NAVI-STAR catheter houses a Biosense Webster ..., exact location points from within the heart whil...rmation. The NAVI-STAR electro-anatomical navigati...
For Tricuspid Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters for mapping in the atrium. The HALO XP 20-pole deflectable catheter is designed for simple placement and
Medicine Products: